Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

  • Cyramza indication extendedSubscription

    The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung ...

  • Revolade for idiopathic ITPSubscription

    The indication of Revolade (eltrombopag; Novartis) has been extended to include adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

  • Daklinza licence extensionSubscription

    Daklinza (daclatasvir; Bristol Myers Squibb), used in combination with other drugs to treat hepatitis C, has been approved for extended use for patients co-infected with HIV and also post liver transplantation by the European Medicines Agency. 

  • Trobalt side effectsSubscription

    The summary of product characteristics for Trobalt (retigabine; GlaxoSmithKline), used to treat epilepsy, now includes acquired vitelliform maculopathy as a common adverse reaction. The update also warns that elderly patients may experience certain central nervous system events, including somnolence, amnesia, vertigo and tremors. 

Other product updates

  • Desmopressin patient safety alertSubscription

    A patient safety alert has been issued by NHS England to raise awareness of the risk of severe dehydration and death caused by an omission or delay of desmopressin in patients with cranial diabetes insipidus. Following reports of patient safety incidents caused by an omission or delay in the provision of desmopressin, providers of NHS care are asked to consider if immediate action needs to be taken locally to raise awareness and reduce the risk of these incidents from occurring. The

  • NICE recommends nintedanibSubscription

    The National Insitute for Health and Care Excellence (NICE) has recommended nintedanib as an option for treating idiopathic pulmonary fibrosis if the person has between 50% and 80% of their predicted forced vital capacity (FVC); the company provides nintedanib with the discount agreed in the patient access scheme; and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period. Further details can be found on the

  • NICE does not recommend ramucirumabSubscription

    The National Institute for Health and Care Excellence (NICE) has not recommended ramucirumab alone or with paclitaxel for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. However, people whose treatment with ramucirumab was started before this guidance was published should be able to continue treatment until they and their clinician consider it appropriate to stop. Further details can be found on the

  • NICE recommends panobinostatSubscription

    The National Institute for Health and Care Excellence (NICE) has recommended panobinostat in combination with bortezomib and dexamethasone, within its marketing authorisation, as an option for treating multiple myeloma, that is, for “adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent” when the company provides panobinostat with the discount agreed in the patient access scheme. ...

Other notifications

  • ONtrack preregistration assessment updateSubscription

    ONtrack, the online pharmacy revision site, has now been updated to reflect the recent changes to the 2016 General Pharmaceutical Council preregistration assessment. ONtrack still offers practice under timed conditions and a comparison of revision progress with other users. If you are a preregistration associate member of the Royal Pharmaceutical Society, you will still be entitled to 30 days free access as part of your membership. More information can be found on the

  • Consultation skills Subscription

    The Centre for Pharmacy Postgraduate Education (CPPE) has launched a new consultation skills resource designed for use by the whole community pharmacy team. The resource is a set of cards which aim to provide flexible learning and quick reminders on effective consultation skills for patient-facing staff. The cards can be

  • Rash in pregnancySubscription

    Public Health England (PHE) has issued new guidance on the management of viral rash during pregnancy. It updates the last guidance issued in 2000 and covers rubella, parvovirus B19, and chickenpox infection and exposure in pregnancy and it has been extended to cover measles infection. The guidance can be accessed via the

  • Oral anticoagulant toolkitSubscription

    Pfizer has published a toolkit on oral anticoagulants designed to help community pharmacy teams to deliver medicines use reviews (MURs) and the new medicines service. The toolkit was developed in consultation with Community Pharmacy West Yorkshire, Yorkshire and Humber Academic Health Science Network and the Leeds Teaching Hospitals NHS Trust. It has also been endorsed by the Pharmaceutical Services Negotiating Committee and Pharmacy Voice.

Other resources

  • Help with medicines translation for migrantsSubscription

    The International Pharmaceutical Federation (FIP) has created a tool kit for pharmacists working in developing countries called a Migrant Advisory document. Members of the Royal Pharmaceutical Society’s Humanitarian Aid and Development Network (HARN) have been helping with translating a table of terms relating to helping people with their medicines. All languages used by those likely to be arriving in Europe need to be included. If you would like to help with non-European translations, ...

  • Research funding for pharmacistsSubscription

    Pharmacy Research UK is now accepting applications from pharmacists wishing to develop skills and experience in research relating to their practice. 

Other opportunities

  • Consultation on non-Hodgkin's lymphomaSubscription

    The National Institute for Health and Care Excellence (NICE) has issued draft guidance for consultation on the management of non-Hodgkin’s lymphoma in adults and young people. The consultation is open to all people involved in providing care for patients with non-Hodgkin’s lymphoma and the document can be accessed via the

  • NHS England consultation on new productsSubscription

    NHS England has launched a consultation on clinical commissioning policies regarding specific products and also service specifications. Responses can be submitted via the NHS England website until 27 February 2016.   

  • Pharmacy Voice patient safety surveySubscription

    Pharmacy Voice is running an anonymous survey for community pharmacy staff to gather views on current patient safety incident reporting and learning processes. The survey is available from the Pharmacy Voice website until early February 2016. 

  • NICE recommends canagliflozin, dapagliflozin and empagliflozinSubscription

    The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending canagliflozin, dapagliflozin and empagliflozin as options for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control. The drugs are also recommended for whom metformin is contraindicated or not tolerated, if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. ...

Other consultations

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs